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Abstract 
Introduction: Whilst some cases of intrapartum fetal compromise are the result of unpredictable 
catastrophic events, the majority arise from an unrecognised reduction in feto-placental reserve in 
otherwise healthy pregnancies. There is currently no reliable technique prior to labour that identifies 
the at-risk fetus. We aimed to investigate the relationship between maternal levels of serum 
placental growth factor (PlGF) and intrapartum fetal compromise in term pregnancies prior to 
labour. Secondary outcomes were caesarean delivery for intrapartum fetal compromise and adverse 
neonatal outcomes. 
 
Methods: A blinded, prospective, cross sectional study set at Mater Mother's Hospital, Brisbane, 
Australia. Maternal PlGF concentration was assessed fortnightly from 36 weeks until delivery in 378 
low-risk pregnant women. Antenatal and intrapartum care was managed according to local 
protocols and guidelines, and intrapartum and neonatal outcomes were recorded.  
 
Results: Pregnancies that developed intrapartum fetal compromise had lower PlGF than those that 
did not. PlGF concentration was also lower amongst pregnancies that developed intrapartum fetal 
heart rate abnormalities, were delivered with abnormal cord gases or Apgar ≤ 7 at 5 minutes. 
Additionally, PlGF levels were lower in pregnancies with an adverse composite neonatal outcome. 
 
Discussion: Lower maternal PlGF concentration is associated with intrapartum fetal compromise and 
poorer condition of the newborn. Maternal PlGF levels may be useful as a component of a risk 
stratification tool for intrapartum fetal compromise in apparently 'low risk' term pregnancies prior to 
labour. 
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Main text 1 
Introduction  2 
In normal uncomplicated labour there is intermittent reduction of placental gas exchange 3 
which results in a fall in fetal pH and oxygen tension and a rise in carbon dioxide and base 4 
deficit levels. The majority of fetuses enter labour with relatively large feto-placental 5 
reserves that helps mitigate the repeated brief reductions in oxygen supply during 6 
contractions. Nevertheless, the net effect of these regular “hypoxic” episodes may be 7 
amplified in vulnerable fetuses and thus they are likely to become gradually compromised 8 
by otherwise normal labour.  9 
 10 
Why some fetuses are prone to intrapartum compromise is not entirely clear. If not 11 
delivered rapidly enough, these babies are at risk of hypoxic brain injury and subsequent 12 
disability with hypoxic ischaemic encephalopathy (HIE) being the strongest and most 13 
consistent risk factor for cerebral palsy in term infants. [1, 2] Current antenatal risk 14 
classification fails to identify up to 63% of pregnancies that result in intrapartum hypoxia.[3] 15 
Various Cochrane systematic reviews have thus consistently highlighted the lack of an 16 
effective technique for risk stratification for not only intrapartum fetal compromise (IFC) but 17 
also for other adverse perinatal outcomes.[4, 5]  18 
 19 
 A technique which can reliably identify term babies who are at risk of compromise in labour 20 
will address a critically unmet need in obstetrics. Although there is currently no good 21 
antenatal or intrapartum tool for this, some placental biomarkers hold promise.[6, 7] One 22 
such candidate is Placental Growth Factor (PlGF), a potent angiogenic factor produced 23 
predominantly by the placenta, which, together with other paracrine and endocrine 24 
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chemicals, helps establish a low resistance placental circulation.[8] Low maternal plasma 25 
levels of PlGF have been associated with early onset pre-eclampsia[5, 9] and fetal growth 26 
restriction,[10-12] conditions that share a common placental aetiology. The association 27 
between maternal PlGF and IFC in women with apparently low-risk pregnancies has not 28 
been investigated. 29 
 30 
The aim of this study was to investigate the relationship between PlGF levels in late 31 
pregnancy and IFC, the need for emergency operative delivery and neonatal outcomes. We 32 
hypothesised that women with normally grown fetuses but low plasma PlGF levels would be 33 
at increased risk of emergency operative delivery for intrapartum compromise, intrapartum 34 
fetal heart rate abnormalities and poorer condition of the newborn. 35 
 36 
  37 
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Methods  38 
This was a blinded, prospective, cross sectional study conducted at the Mater Mothers’ 39 
Hospital in Brisbane, Australia between May 2014 and March 2016. This is the largest 40 
maternity hospital in Australia, with a current birth rate of approximately 10,500 babies 41 
annually. Women attending the outpatient antenatal clinic for routine assessment from 28 42 
weeks gestation were screened by research midwives for eligibility and provided with an 43 
information leaflet inviting them to participate in the study. Inclusion criteria were women 44 
with uncomplicated, non-anomalous singleton pregnancies with a normally grown fetus on 45 
routine clinical assessment who were anticipating a vaginal delivery. Exclusion criteria 46 
included known fetal growth restriction, multiple pregnancy, previous caesarean, pre-47 
eclampsia/pregnancy induced hypertension, and maternal age <18 or >50 years. Fetal 48 
growth restriction was defined as estimated fetal weight <10
th
 centile and umbilical artery 49 
pulsatility index >95
th
 centile for gestation.[13] Ethical and governance approvals were 50 
granted by the Mater Human Research Ethics Committee and Research Governance Office 51 
respectively (Ref no: HREC/13/MHS/173) prior to study commencement. 52 
 53 
Gestational age was calculated based on a first trimester ultrasound scan. All women had a 54 
venous sample taken fortnightly from 36 weeks (+/- 1 week) and PlGF concentration 55 
quantified within 4 hours using the Triage PlGF Test (Alere, San Diego, CA) and DELFIA 56 
Xpress immunoassay (PerkinElmer, Turku, Finland). The Triage platform requires a 250µL 57 
EDTA plasma sample and reports concentration in the range 12-3000pg/ml with an overall 58 
coefficient of variation of 12.8-13.2%.[14] The DELFIA platform requires a 40µL SST plasma 59 
sample and reports a concentration in the range 7-4000 pg/mL with an overall coefficient of 60 
variation of 10.1-5.1% (at 27.6 pg/mL and 74.2 pg/mL, respectively). A correction algorithm 61 
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was developed following parallel testing between the Triage and DELFIA systems on 50 62 
samples and the values reported are the DELFIA equivalents. Quality control was performed 63 
routinely as specified by the manufacturers. PlGF concentrations reported are the last 64 
obtained prior to delivery. Women and clinicians were blinded to the PlGF results. Labour 65 
and delivery were managed according to local protocols and guidelines. 66 
 67 
The primary outcome measure was IFC (based on intrapartum fetal heart rate (FHR) 68 
abnormalities, abnormal fetal scalp lactate, or both) requiring emergency delivery (either 69 
instrumental or caesarean birth). Intrapartum FHR patterns were classified according to The 70 
Royal Australian and New Zealand College of Obstetricians and Gynaecologists 71 
guidelines.[15] Secondary outcome measures were mode of delivery, presence of a 72 
suspicious or pathological intrapartum FHR pattern, presence of meconium-stained liquor, 73 
acidosis at birth (umbilical cord arterial pH ≤ 7.1 or lactate ≥ 6 mmol/L), Apgar score ≤ 7 at 74 
five minutes, Neonatal Intensive Care Unit (NICU) admission and an adverse composite 75 
neonatal outcome (cord arterial pH ≤ 7.1 or lactate ≥ 6 mmol/L or Apgar score ≤ 7 at 5 76 
minutes or NICU admission). 77 
 78 
Statistical analysis 79 
Participants were divided into four groups for comparison of clinical characteristics: those 80 
with no IFC and spontaneous vaginal delivery; those with no IFC and operative delivery 81 
(instrumental or caesarean); those with IFC and instrumental delivery, and those with IFC 82 
and caesarean section. Maternal (age, parity, ethnicity, BMI and serum PlGF) and infant 83 
(birthweight, birthweight centile, gestational age at delivery) characteristics were compared 84 
using a Fisher’s exact test for frequencies, or ANOVA or Kruskal-Wallis test, for normally 85 
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distributed or non-normally distributed continuous variables respectively. Spearman’s rho 86 
was used to assess correlations between PlGF levels, birthweight and birthweight centiles. 87 
Associations between PlGF, intrapartum and neonatal outcomes were assessed using 88 
Wilcoxon’s rank-sum test (Mann-Whitney U test). The significance level for all analyses was 89 
set at p ≤ 0.05. Statistical analysis was performed with Stata software (version 13.0). 90 
 91 
  92 
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Results 93 
Of the three hundred and eighty five women who volunteered to participate, seven were 94 
ineligible resulting in 378 women who were finally recruited to the study. Thirty six (9.5%) 95 
women were excluded for various reasons from the final analysis: 14 (3.7%) eventually had 96 
a planned caesarean either due to a change in their mode of birth preference or because of 97 
malpresentation, 19 (5.0%) did not have intrapartum electronic fetal heart rate monitoring, 98 
2 (0.5%) had births complicated by severe shoulder dystocia and 1 (0.3%) had severe 99 
intrapartum urosepsis precipitating fetal compromise.  Therefore the final study cohort 100 
consisted of 342 women. The participant flow diagram is presented in Figure 1. Of the final 101 
study cohort, 23 women had newborns with gender and gestation specific birth weights 102 
<10
th
 centile.  103 
Emergency intervention for fetal compromise occurred in 18.1% (62/248) of the study 104 
cohort. Of these, 3.5% (12/342) required emergency caesareans and 14.6% (50/342) 105 
required instrumental delivery (Table 1). Of the 342 women, 49% (169/342) had umbilical 106 
artery cord blood gases performed. Of the 12 women who underwent emergency caesarean 107 
for IFC, all had a degree of fetal heart rate abnormality that was sufficient to precipitate 108 
delivery. Additionally, 8.3% (1/12) had fetal scalp lactates performed which prompted 109 
delivery. No emergency caesarean deliveries occurred prior to 37 weeks gestation.  110 
Both PlGF assay platforms passed all quality control checks as specified by the manufacturer 111 
during the study period. Further testing using maternal samples from this study confirmed a 112 
coefficient of variation of 12.8-16.3%. Maternal PlGF levels were significantly lower in 113 
pregnancies that developed IFC and required any assisted delivery (caesarean or 114 
instrumental) compared to those that did not, as shown inTable 2. Sub-group analysis of 115 
PlGF by mode and indication for delivery again showed lower median PlGF levels amongst 116 
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pregnancies delivered by emergency caesarean or instrumental delivery for IFC, either in 117 
isolation (89 pg/mL, IQR 62 - 132, n = 12, p = 0.04 and 90 pg/mL, IQR 69 - 263, n = 50, p = 118 
0.05; respectively) or combined (90.2 pg/mL, IQR 67 - 186, n = 62, p = 0.004), compared to 119 
all other modes of delivery without IFC (139 pg/mL, IQR 85 – 265, n = 279).  120 
 121 
Additionally, PlGF levels were significantly lower in pregnancies that had 122 
suspicious/pathological intrapartum FHR patterns, delivered babies with abnormal cord 123 
artery pH or lactate or with an adverse composite neonatal outcome. PlGF concentrations in 124 
pregnancies with meconium-stained liquor or NICU admission, compared to those without, 125 
were however not significantly different. These relationships remained even when we 126 
excluded the 23 women who had newborns with birth weights <10
th
 centile. (Table 2).  127 
 128 
Birthweight and birthweight centile were correlated with maternal PlGF levels (rho = 0.17 129 
and rho = 0.19, p = 0.002 and p = 0.0004, respectively). 130 
 131 
  132 
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Discussion 133 
Our results show that maternal PlGF levels measured in the final month of pregnancy in 134 
otherwise ‘low risk’ women at term with appropriately grown fetuses were lower in those 135 
who required emergency delivery for IFC. Maternal PlGF levels were also lower in women 136 
who had non-reassuring intrapartum FHR patterns and those whose babies had poorer 137 
neonatal outcomes.  138 
 139 
Low PlGF levels are known to be associated with placental underperfusion,[12] growth 140 
restriction,[16] pre-eclampsia and other adverse pregnancy outcomes.[17-19] Indeed, 141 
serum PlGF concentration in early pregnancy appears to have particular promise as a 142 
predictor for the early detection of pre-eclampsia.[20] However, its relationship with IFC has 143 
never previously been prospectively investigated in a ‘low risk’, term population. Whilst 144 
there is evidence, predominantly from retrospective studies with unselected populations, 145 
that biomarkers of impaired placentation (including PlGF and s-Flt) measured earlier in 146 
pregnancy (30 - 37 weeks) have reasonable predictive value for pre-eclampsia, small for 147 
gestational age fetus, and fetal distress before labour, these biomarkers had poor or no 148 
predictive value for adverse events in labour or after birth.[21, 22] Our results are in 149 
contrast to these findings in that we demonstrate a clear prospective association between 150 
low PlGF levels and intrapartum fetal compromise and adverse neonatal outcomes in the 151 
last four weeks of pregnancy at term. Although median PlGF levels were lower in women 152 
that developed IFC as well as for stated neonatal outcomes, there was considerable overlap 153 
in values between the groups, thus limiting implementation at this stage. Our study was not 154 
powered to detect rarer adverse events such as hypoxic ischaemic encephalopathy or 155 
stillbirth and these need to be investigated in future studies.  156 
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 157 
Our findings also support the notion that in the majority of cases IFC occurs as a 158 
consequence of gradual deterioration of placental oxygen/nutrient transfer to the fetus in 159 
the context of subtle placental dysfunction, which then precipitates deterioration of the 160 
fetal condition during uterine contractions in labour. Such dysfunction, as reflected by the 161 
lower maternal PlGF levels demonstrated in our study, may be identifiable at least two 162 
weeks before birth. Other screening methods, such as the fetal cerebroumbilical ratio (also 163 
known as the cerebroplacental ratio; a marker of cerebral redistribution or “brain sparing”), 164 
has also been reported to identify fetuses at risk of intrapartum compromise, emergency 165 
intrapartum caesarean, poor condition at birth and neonatal unit admission[23-31] albeit 166 
with detection rates that preclude its incorporation into current clinical practice. 167 
Experimental studies suggest that fetuses that exhibit greater cardiovascular adaptation (i.e. 168 
cerebral redistribution) have reduced fetal reserve that would be exposed during hypoxic 169 
insults.[32]   170 
 171 
Currently, IFC is generally diagnosed by electronic fetal heart rate monitoring and 172 
subsequently managed via rapid emergency delivery. There are three shortcomings with 173 
this reactive model of care. Firstly, hypoxic brain injury may already have occurred in labour. 174 
Secondly, emergency caesarean places the mother and fetus at increased risk of poorer 175 
outcomes than the non-emergency equivalent. Thirdly, the woman is not forewarned of the 176 
risks of IFC specific to her and its immediate and possible longer term sequelae to her 177 
offspring, particularly the risk of adverse neurological outcome in the event of hypoxic brain 178 
injury.  179 
 180 
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 181 
The strengths of this study are the inclusion of only women who would not generally be 182 
considered at high risk of fetal compromise. Furthermore, the incidence of pregnancy 183 
induced hypertension was similar in all modes of birth regardless of the presence of 184 
intrapartum fetal compromise. The measurement of PlGF levels was also consistently 185 
performed serially within two weeks of birth. Limitations of this study were its relatively 186 
small study cohort, the low incidence of intrapartum fetal compromise and the 187 
appropriateness of the components of the adverse neonatal outcome composite.  188 
 189 
The ability to risk stratify pregnant women for IFC or adverse neonatal outcomes before 190 
labour commences would therefore challenge the current paradigm of obstetric care. Our 191 
findings suggest that PlGF may complement standard clinical risk assessment measures and 192 
assist in risk stratification for pregnancies at term. The clinical relevance of this is self-193 
evident. A woman at high risk of poor perinatal outcome could be offered expedited 194 
delivery or more intensive surveillance following a more cogent discussion of the risks of 195 
continuing the pregnancy. Knowledge of the risk of IFC could influence the choice of both 196 
mode and timing of birth. Women at significant risk of IFC could be offered elective birth 197 
which would reduce the number of emergency caesarean sections performed and improve 198 
maternal and neonatal outcomes. Emergency procedures often carry more risk of 199 
complications, more parental anxiety, cost more and often occur out of hours when staffing 200 
is less than optimal. The assignment of women to a “low risk” category would also allow 201 
maternity care to be individualised. The majority of women who are deemed to be low risk 202 
for fetal compromise could be given the option of birth without continuous electronic fetal 203 
monitoring either in a midwifery unit or possibly at home (depending on the health care 204 
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setting). Conversely, continuous electronic fetal heart rate monitoring could be reserved 205 
only for women at increased risk of this complication. Recently, PlGF has been shown to be 206 
a promising tool for antenatal discrimination of growth restricted fetuses from those that 207 
are constitutionally-small. [16] Given this finding, the fact that this cohort of fetuses is much 208 
more prone to compromise in labour and the results of our study, it is conceivable that 209 
incorporating PlGF as a component of a screening test for these complications is a 210 
possibility. Clearly further work is required with a larger cohort of women to ascertain the 211 
performance characteristics of PlGF as a screening test. 212 
 213 
 214 
 215 
  216 
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Figure 1. Participant flow diagram 225 
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 242 
CTG, cardiotocograph; SVD, spontaneous vaginal delivery; IFC, delivery for which 243 
intrapartum fetal compromise was the primary indication for delivery.  244 
  245 
378 women 
14 elective caesareans  
364 anticipated vaginal 
deliveries 
2 shoulder dystocia 
1 uroseptic woman 
 
361 deliveries 
280 vaginal deliveries 62 caesarean deliveries 
180 SVD
 
 50 instrumental 
(IFC) 
12 caesarean 
(IFC) 
50 caesarean 
(no IFC) 
50 instrumental 
(no IFC) 
19 CTGs unavailable  
 
342 deliveries included  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 1. Participant characteristics 246 
Characteristic Overall, n No IFC       
SVD 
No IFC  
operative 
IFC 
instrumental 
IFC CS p-value 
Women, n (%) 342 180 (53%) 100 (29%) 50 (15%) 12 (3.5%)  
Maternal age 29.7 (4.5) 29.4 (4.7) 30 (4.3) 30.4 (3.9) 29.1 (3.8) 0.42
a
 
Parity       
P0      2986 (84%) 1538 (77%) 90 (90%) 47 (94%) 11 (92%)  
>P1 56 (16%) 42 (23%) 10 (10%) 3 (6%) 1 (8%) 0.003
b
 
Ethnicity       
Caucasian 215 (63%) 114 (63.3%) 62 (62%) 31 (62%) 8 (66.7%)  
East Asian 56 (16%) 28 (15.6%) 19 (19%) 8 (16%) 1 (8.3%)  
Asian 37 (11%) 16 (8.9%) 12 (12%) 7 (14%) 2 (16.7%)  
Other 34 (10%) 22 (12.2%) 7 (7%) 4 (8%) 1 (8.3%) 0.85
b
 
BMI 23 (21 – 26) 23 (21 – 26) 23 (21-25) 24 (21-26) 23 (20-28) 0.89
c
 
Hypertension 15 (4.2%) 7 (3.9%) 4 (6.0%) 3 (20%) 1 (8.3%) 0.59
b
 
Diabetes 28 (8.2%) 15 (8.3%) 11 (11%) 2 (4%) 0 (0%) - 
GA delivery  40 (39.1-40.9) 40 (39.1-40.7) 40.1 (39.3-41) 40.1 (39.3-41.3) 40.2 (39.5-40.6) 0.19
c
 
BW (g) 3429 (438) 3390 (416) 3598 (462) 3282 (382) 3223 (347) <0.001
a 
BW centile 46 (26) 46 (25) 54 (27) 36 (22) 30 (17) <0.001
a 
 247 
IFC, intrapartum fetal compromise; CS, caesarean for intrapartum fetal compromise; BW, 248 
birthweight (grams); GA delivery, gestational age at delivery (weeks). BMI, body mass index 249 
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(kg/m
2
); and GA, gestational age at delivery (weeks) reported as medians and IQRs. 250 
Categorical variables reported as n (%). 251 
Normally distributed variables (maternal age, BW and BW centile) are reported as means 252 
(SD). Non-normally distributed variables (BMI and GA) are reported as medians (95% CI).  253 
a 
One way ANOVA 254 
b 
Fisher’s exact test 255 
c 
Kruskal-Wallis test 256 
  257 
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Table 2: PlGF levels, intrapartum and neonatal outcomes 258 
Outcome No Yes p
a
  
IFC  139 (84-265, n=279) 90 (67-186, n=62) 0.003 
 140 (85-267, n=265) 96 (69-206, n=53) 0.02 
Abnormal FHR 148 (92 – 297, n=211) 98 (69 – 183, n=130) <0.001 
 149 (92 – 301, n=201) 99 (70 – 185, n=117) <0.001 
Meconium stained liquor 128 (79 – 270, n=247) 123 (81 – 221, n=94) 0.51 
 134 (77 – 270, n=232) 126 (89 – 228, n=86) 0.86 
Abnormal cord gases 132 (85-228, n=119) 94 (69-124, n=50) 0.02 
 134 (86-238, n=111) 95 (69-124, n=45) 0.01 
Apgar ≤7 @ 5 minutes 128 (80-263, n=326) 80 (64-124, n=15) 0.02 
 134 (81-268, n=326) 86 (64-124, n=14) 0.03 
NICU admission 125 (79 – 263, n=333) 118 (86 – 154, n=14) 0.70 
 129 (79 – 269, n=294) 118 (82 – 191, n=12) 0.61 
Adverse composite  140 (83-270, n=280) 94 (70-142, n=61) 0.002 
neonatal outcome 143 (85-272, n=264) 95 (69-142, n=54) 0.002 
 259 
Columns ‘No’/’Yes’ report PlGF values according to whether the specified outcome did or 260 
did not occur. Italicised rows indicate sub-analysis with 23 SGA babies (birthweight <10
th
 261 
centile) excluded. PlGF (pg/mL) values reported are medians and IQRs.  262 
IFC, intrapartum fetal compromise (based on intrapartum FHR abnormalities, fetal scalp 263 
lactate sampling, or both); abnormal FHR, suspicious or pathological fetal heart rate as 264 
specified in methods; abnormal cord gases, umbilical artery pH≤7.1 or lactate ≥6, NICU, 265 
neonatal intensive care unit; adverse neonatal composite, abnormal cord gases and/or 266 
Apgar ≤7 at 5 minutes and/or NICU admission.  267 
a 
Wilcoxon rank sum test (Mann-Whitney U test) 268 
  269 
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Highlights 
1. Infants with intrapartum fetal compromise had lower placental growth factor levels than 
those with spontaneous vaginal deliveries. 
2. Infants who were delivered for intrapartum fetal compromise had lower placental 
growth factor levels than those with spontaneous vaginal deliveries  
3. Infants with an adverse composite neonatal outcome had lower placental growth factor 
levels than those with a normal neonatal outcome. 
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